Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates
Company plans to initiate a Phase 2 SEISMiC extension study of istaroxime in early cardiogenic shock in Q3; Study start-up for a Phase 2 SCAI Stage C cardiogenic shock study underway Completed $12.4 million public offering including full exercise of overallotment option WARRINGTON, Pa. , Aug.
Article Date
August 7, 2023
This article is featured on another website.
Go to article
January 28, 2026
Why Australia & New Zealand Are Smart Alternatives for Your Clinical Trial During FDA Uncertainty
Navigating the Next Few Years with Confidence 2025 has been marked by significant regulatory…
January 28, 2026
Why Australia & New Zealand Are Smart Alternatives for Your Clinical Trial During FDA Uncertainty
Navigating the Next Few Years with Confidence 2025 has been marked by significant regulatory…
January 29, 2026
Rescuing a Rare Disease Trial: Accelerating MRCT RA Submissions for a Taiwan Biotech Company
This case study highlights HiRO's effective intervention in accelerating the regulatory submission process for a…
January 29, 2026
Rescuing a Rare Disease Trial: Accelerating MRCT RA Submissions for a Taiwan Biotech Company
This case study highlights HiRO's effective intervention in accelerating the regulatory submission process for a…